Top Markets
Coin of the day
Modalis Therapeutics Corporation Modalis Therapeutics Corporation

Modalis Therapeutics Corporation

4883
Rang in Aktien #29675
Modalis Therapeutics Corporation focuses on discovering and developing... Modalis Therapeutics Corporation focuses on discovering and developing treatments for severe genetic conditions. The company utilizes its proprietary CRISPR-GNDM technology to create therapies by controlling gene expression through the epigenetic modulation of specific genetic loci. Modalis also has a collaborative research agreement with JCR Pharmaceuticals Co., Ltd., aimed at assessing gene therapy drug delivery methods for the central nervous system (CNS), particularly for CNS-related disorders. Founded in 2016, the company was initially known as EdiGENE Corporation before changing its name to Modalis Therapeutics Corporation in August 2019. Its operations are based in Tokyo, Japan.
Aktienkurs
$0.20877985
Marktkapitalisierung
$20.11M
Veränderung (1 Tag)
-3.03%
Veränderung (1 Jahr)
-66.13%
Land
JP
Handel Modalis Therapeutics Corporation (4883)

Kategorie

Dividendenrendite-Verlauf für Modalis Therapeutics Corporation (4883)
Dividendenrendite (TTM) von Modalis Therapeutics Corporation (Aktienkürzel: 4883) zum 2026: 0
Durchschnittliche Dividendenrendite der letzten 5 Jahre: 0.00%
Dividendenrendite-Verlauf für Modalis Therapeutics Corporation (4883) von 2026 bis 2026
Dividendenrendite am Ende jedes Jahres (TTM)
Jahr Dividendenrendite ändert
Nicht genügend Daten für die angegebenen Daten.
Dividendenrenditen (TTM) für ähnliche Unternehmen oder Wettbewerber